Market Closed -
OTC Markets
07:39:57 09/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.15
USD
|
+87.50%
|
|
+36.36%
|
+322.54%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2.661
|
1.054
|
4.817
|
8.609
|
1.71
|
0.361
|
Enterprise Value (EV)
1 |
3.123
|
1.044
|
5.311
|
8.803
|
2.382
|
1.472
|
P/E ratio
|
-0.25
x
|
0.25
x
|
-0.54
x
|
-6.49
x
|
-0.46
x
|
-0.24
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
167
x
|
17
x
|
598
x
|
1,853
x
|
502
x
|
0.46
x
|
EV / Revenue
|
196
x
|
16.8
x
|
659
x
|
1,895
x
|
699
x
|
1.87
x
|
EV / EBITDA
|
-0.43
x
|
0.35
x
|
-1.32
x
|
-9.15
x
|
-
|
-1.01
x
|
EV / FCF
|
1.52
x
|
-0.64
x
|
4.53
x
|
-12.7
x
|
0.93
x
|
7.86
x
|
FCF Yield
|
65.9%
|
-156%
|
22.1%
|
-7.89%
|
108%
|
12.7%
|
Price to Book
|
-5.32
x
|
-24.7
x
|
-7.95
x
|
167
x
|
-3
x
|
-0.21
x
|
Nbr of stocks (in thousands)
|
1,116
|
2,342
|
5,098
|
7,085
|
8,446
|
10,168
|
Reference price
2 |
2.385
|
0.4500
|
0.9450
|
1.215
|
0.2025
|
0.0355
|
Announcement Date
|
14/12/18
|
16/12/19
|
18/12/20
|
24/03/22
|
27/04/23
|
18/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.0159
|
0.0621
|
0.008054
|
0.004646
|
0.003407
|
0.7855
|
EBITDA
1 |
-7.19
|
3.018
|
-4.013
|
-0.9623
|
-
|
-1.463
|
EBIT
1 |
-7.191
|
3.014
|
-4.015
|
-0.3202
|
-4.021
|
-1.472
|
Operating Margin
|
-45,169.66%
|
4,853.6%
|
-49,853.91%
|
-6,892.45%
|
-1,18,011.59%
|
-187.4%
|
Earnings before Tax (EBT)
1 |
-7.61
|
2.581
|
-4.641
|
-0.0253
|
-4.116
|
-1.483
|
Net income
1 |
-7.61
|
2.581
|
-4.641
|
-0.0253
|
-4.116
|
-1.483
|
Net margin
|
-47,801.73%
|
4,155.61%
|
-57,621.13%
|
-544.68%
|
-1,20,816.76%
|
-188.79%
|
EPS
2 |
-9.671
|
1.800
|
-1.757
|
-0.1872
|
-0.4400
|
-0.1500
|
Free Cash Flow
1 |
2.058
|
-1.627
|
1.172
|
-0.6949
|
2.564
|
0.1874
|
FCF margin
|
12,931.06%
|
-2,620.35%
|
14,552.06%
|
-14,956.26%
|
75,249.84%
|
23.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/12/18
|
16/12/19
|
18/12/20
|
24/03/22
|
27/04/23
|
18/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.46
|
-
|
0.49
|
0.19
|
0.67
|
1.11
|
Net Cash position
1 |
-
|
0.01
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.0643
x
|
-
|
-0.123
x
|
-0.202
x
|
-
|
-0.7594
x
|
Free Cash Flow
1 |
2.06
|
-1.63
|
1.17
|
-0.69
|
2.56
|
0.19
|
ROE (net income / shareholders' equity)
|
2,175%
|
-1,124%
|
1,702%
|
207%
|
-625%
|
124%
|
ROA (Net income/ Total Assets)
|
-2,394%
|
1,259%
|
-2,043%
|
-415%
|
-173%
|
-241%
|
Assets
1 |
0.3178
|
0.2049
|
0.2272
|
0.006096
|
2.375
|
0.6157
|
Book Value Per Share
2 |
-0.4500
|
-0.0200
|
-0.1200
|
0.0100
|
-0.0700
|
-0.1700
|
Cash Flow per Share
2 |
0.0800
|
0.0100
|
0.0300
|
0.0200
|
0
|
0
|
Capex
|
-
|
-
|
0
|
0
|
0.01
|
-
|
Capex / Sales
|
-
|
-
|
34.08%
|
59.08%
|
211.39%
|
-
|
Announcement Date
|
14/12/18
|
16/12/19
|
24/03/22
|
24/03/22
|
27/04/23
|
18/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +322.54% | 813K | | +32.36% | 698B | | +26.51% | 568B | | -4.40% | 358B | | +19.46% | 328B | | +3.50% | 283B | | +16.34% | 238B | | +6.68% | 203B | | -9.08% | 198B | | +8.62% | 165B |
Other Pharmaceuticals
|